Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis
Purpose: The purpose of this study was to evaluate the efficacy and toxicity of a novel lanthanum compound, La(XT), in an ovariectomized (OVX) rat model of osteoporosis. Methods: Twenty-four ovariectomized female Sprague Dawley rats were divided into 3 groups receiving a research diet with/without t...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Bone Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352187221000085 |
id |
doaj-fac871169e1141f6bfd54cfe9719e150 |
---|---|
record_format |
Article |
spelling |
doaj-fac871169e1141f6bfd54cfe9719e1502021-06-03T04:57:20ZengElsevierBone Reports2352-18722021-06-0114100753Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosisYunyun Di0Ellen K. Wasan1Jacqueline Cawthray2Jaweria Syeda3Munawar Ali4David M.L. Cooper5Ahmad Al-Dissi6Nima Ashjaee7Wubin Cheng8James Johnston9David M. Weekes10Thomas I. Kostelnik11Chris Orvig12Kishor M. Wasan13College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaDepartment of Anatomy Physiology and Pharmacology, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, CanadaWestern College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4, CanadaCollege of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, CanadaCollege of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, CanadaCollege of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, CanadaMedicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, CanadaMedicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, CanadaMedicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, Canada; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Corresponding author at: Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Canada.Purpose: The purpose of this study was to evaluate the efficacy and toxicity of a novel lanthanum compound, La(XT), in an ovariectomized (OVX) rat model of osteoporosis. Methods: Twenty-four ovariectomized female Sprague Dawley rats were divided into 3 groups receiving a research diet with/without treatment compounds (alendronate: 3 mg/kg; La(XT) 100 mg/kg) for three months. At the time of sacrifice, the kidney, liver, brain, lung and spleen were collected for histological examination. The trabecular bone structure of the tibiae was evaluated using micro-CT and a three-point metaphyseal mechanical test was used to evaluate bone failure load and stiffness. Results: No significant differences were noted in plasma levels of calcium, phosphorus, creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) between the La(XT) treatment compared to the non-treated OVX group. Alendronate-treated animals (positive control) showed higher BV/TV, Tb.N and lower Tb.Th and Tb.Sp when compared to the non-treated OVX group. Mechanical analysis indicated that stiffness was higher in the alendronate (32.88%, p = 0.04) when compared to the non-treated OVX group. Failure load did not differ among the groups. Conclusions: No kidney or liver toxicities of La(XT) treatments were found during the three-month study. The absence of liver and kidney toxicity with drug treatment for 3 months, as well as the increased trabecular bone stiffness are encouraging for the pursuit of further studies with La(XT) for a longer duration of time.http://www.sciencedirect.com/science/article/pii/S2352187221000085OsteoporosisLanthanumLa(XT)OVXToxicity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yunyun Di Ellen K. Wasan Jacqueline Cawthray Jaweria Syeda Munawar Ali David M.L. Cooper Ahmad Al-Dissi Nima Ashjaee Wubin Cheng James Johnston David M. Weekes Thomas I. Kostelnik Chris Orvig Kishor M. Wasan |
spellingShingle |
Yunyun Di Ellen K. Wasan Jacqueline Cawthray Jaweria Syeda Munawar Ali David M.L. Cooper Ahmad Al-Dissi Nima Ashjaee Wubin Cheng James Johnston David M. Weekes Thomas I. Kostelnik Chris Orvig Kishor M. Wasan Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis Bone Reports Osteoporosis Lanthanum La(XT) OVX Toxicity |
author_facet |
Yunyun Di Ellen K. Wasan Jacqueline Cawthray Jaweria Syeda Munawar Ali David M.L. Cooper Ahmad Al-Dissi Nima Ashjaee Wubin Cheng James Johnston David M. Weekes Thomas I. Kostelnik Chris Orvig Kishor M. Wasan |
author_sort |
Yunyun Di |
title |
Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis |
title_short |
Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis |
title_full |
Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis |
title_fullStr |
Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis |
title_full_unstemmed |
Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis |
title_sort |
evaluation of la(xt), a novel lanthanide compound, in an ovx rat model of osteoporosis |
publisher |
Elsevier |
series |
Bone Reports |
issn |
2352-1872 |
publishDate |
2021-06-01 |
description |
Purpose: The purpose of this study was to evaluate the efficacy and toxicity of a novel lanthanum compound, La(XT), in an ovariectomized (OVX) rat model of osteoporosis. Methods: Twenty-four ovariectomized female Sprague Dawley rats were divided into 3 groups receiving a research diet with/without treatment compounds (alendronate: 3 mg/kg; La(XT) 100 mg/kg) for three months. At the time of sacrifice, the kidney, liver, brain, lung and spleen were collected for histological examination. The trabecular bone structure of the tibiae was evaluated using micro-CT and a three-point metaphyseal mechanical test was used to evaluate bone failure load and stiffness. Results: No significant differences were noted in plasma levels of calcium, phosphorus, creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) between the La(XT) treatment compared to the non-treated OVX group. Alendronate-treated animals (positive control) showed higher BV/TV, Tb.N and lower Tb.Th and Tb.Sp when compared to the non-treated OVX group. Mechanical analysis indicated that stiffness was higher in the alendronate (32.88%, p = 0.04) when compared to the non-treated OVX group. Failure load did not differ among the groups. Conclusions: No kidney or liver toxicities of La(XT) treatments were found during the three-month study. The absence of liver and kidney toxicity with drug treatment for 3 months, as well as the increased trabecular bone stiffness are encouraging for the pursuit of further studies with La(XT) for a longer duration of time. |
topic |
Osteoporosis Lanthanum La(XT) OVX Toxicity |
url |
http://www.sciencedirect.com/science/article/pii/S2352187221000085 |
work_keys_str_mv |
AT yunyundi evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT ellenkwasan evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT jacquelinecawthray evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT jaweriasyeda evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT munawarali evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT davidmlcooper evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT ahmadaldissi evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT nimaashjaee evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT wubincheng evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT jamesjohnston evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT davidmweekes evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT thomasikostelnik evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT chrisorvig evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis AT kishormwasan evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis |
_version_ |
1721399778511683584 |